Taniborbactam Effectively Inhibits Pseudomonas-Derived Cephalosporinase

Article

A study presented advocated for combining taniborbactam and cefepime to treat P aeruginosa isolates that develop ESAC phenotypes.

A study presented at IDWeek advocated for combining taniborbactam and cefepime to treat P. aeruginosa isolates that develop ESAC phenotypes.

Pseudomonas-derived cephalosporinase (PDC) is a class C β-lactamase in P aeruginosa. PDC-88 is a variant characterized by a Thr-Pro amino acid deletion in the R2-loop. With this deletion, cefepime (FEP), ceftazidime (CAZ), and ceftolozane-tazobactam (TOL/TZB) susceptibility is reduced. However, the mechanism for this “gain of function” is unknown.

A study presented virtually at the annual IDWeek conference investigated taniborbactam (TAN), a novel cyclic boronate β-lactamase inhibitor (BLI) that works against all four β-lactamase classes. TAN is also currently undergoing a phase 3 clinical trial paired with FEP. In the study, presented by Andrew R. Mack, the investigators studied the extended-spectrum AmpC (ESAC) phenotype of PDC-88 to explore the ability of TAN to inhibit the variant.

The investigators determined broth microdilution minimum inhibitory concentrations (MIC) in accordance with CLSI. They purified PDC-3 and PDC-88 and determined steady-state enzyme kinetics. Finally, they conducted quadrupole time-of-flight mass spectrometry (Q-TOF-MS).

The results showed that in isogenic E coli with PDC-3, FEP MIC increased 8-fold, and in E coli with PDC-88, FEP MIC increased 128-fold. Adding TAN at 4 μg/ml restored FEP activity and lowered MIC to 0.25 μg/ml in PDC-3 and PDC-88 strains. According to the abstract, “PDC-88 demonstrated a 9-fold lower KM, 3.4-fold lower kcat, and 2.6-fold higher kcat/KM for FEP compared to PDC-3. TAN Ki values were 4- to 10-fold lower than avibactam (AVI) and 40- to 95-fold lower than TZB. The TAN acylation constant (k2/K) was 7- to 12-fold greater than AVI and 133- to 366-fold higher than TZB. Q-TOF-MS revealed faster deacylation of FEP by PDC-88 compared to TOL and CAZ. TOL was acylated and deacylated by PDC-88 but not by PDC-3.CAZ was readily acylated but slowly deacylated by PDC-88 compared to PDC-3.”

In all variants, taniborbactam and avibactam restored susceptibility, while tazobactam was less effective against PDC-88 and variants. Different kinetic constants caused the elevated cephalosporin MICs.The results led the investigators to postulate that PDC-88 increases FEP MIC by enhanced hydrolysis, TOL MICs by enabling acylation, and CAZ MICs by both trapping and enhancing hydrolysis. TAN inhibits both PDC-3 and PDC-88 with similar kinetic profiles, and appears to be a more efficient inhibitor of PDC than current BLIs used to combat P. aeruginosa. They concluded that combining TAN and FEP may be a vital treatment option for P. aeruginosa isolates that develop ESAC phenotypes.

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.